Lincoln National Corp’s Regeneron Pharmaceuticals REGN Stock Holding History

Lincoln National Corp’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-668	Closed	-$643K	–	893
2024 Q1	$643K	Sell	668 -103	-13%	-$97.9K	0.01%	656
2023 Q4	$677K	Buy	771 +256	+50%	+$211K	0.01%	572
2023 Q3	$424K	Buy	515 +11	+2%	+$8.64K	0.01%	651
2023 Q2	$362K	Buy	504 +90	+22%	+$69.4K	0.01%	722
2023 Q1	$340K	Buy	414 +38	+10%	+$28.7K	0.01%	727
2022 Q4	$271K	Buy	+376	New	+$277K	0.01%	756
2020 Q1	–	Sell	-651	Closed	-$245K	–	656
2019 Q4	$245K	Buy	+651	New	+$219K	0.01%	552

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Lincoln National Corp's REGN Position: Q2 2024 in Review

Lincoln National Corp sold out of Regeneron Pharmaceuticals (REGN) in Q2 2024, closing a stake of 668 shares — an estimated $643K sold.

Lincoln National Corp first reported a position in REGN in Q4 2019 and held it in 7 quarters. The position peaked at $677K in Q4 2023. 1,331 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

Lincoln National Corp reported no remaining Regeneron Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Lincoln National Corp sold 668 Regeneron Pharmaceuticals shares in Q2 2024, an estimated $643K.
Lincoln National Corp first reported a position in Regeneron Pharmaceuticals in Q4 2019 and held it in 7 quarters.
Lincoln National Corp's Regeneron Pharmaceuticals position peaked at $677K in Q4 2023.
1,331 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on Lincoln National Corp's 13F filing for Q2 2024, filed 25 Jul 2024.